Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Common Equity (2019 - 2026)

Pliant Therapeutics has reported Common Equity over the past 8 years, most recently at $165.2 million for Q1 2026.

  • Quarterly Common Equity fell 35.77% to $165.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $165.2 million through Mar 2026, down 35.77% year-over-year, with the annual reading at $181.2 million for FY2025, 40.41% down from the prior year.
  • Common Equity was $165.2 million for Q1 2026 at Pliant Therapeutics, down from $181.2 million in the prior quarter.
  • Over five years, Common Equity peaked at $561.9 million in Q1 2023 and troughed at $147.8 million in Q2 2022.
  • The 5-year median for Common Equity is $313.3 million (2022), against an average of $326.3 million.
  • Year-over-year, Common Equity soared 260.7% in 2023 and then tumbled 43.95% in 2025.
  • A 5-year view of Common Equity shows it stood at $313.3 million in 2022, then surged by 51.14% to $473.6 million in 2023, then tumbled by 35.79% to $304.1 million in 2024, then crashed by 40.41% to $181.2 million in 2025, then fell by 8.85% to $165.2 million in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Common Equity are $165.2 million (Q1 2026), $181.2 million (Q4 2025), and $200.3 million (Q3 2025).